Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 5/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.32 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.32 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.31 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MPI | P34949 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6095943 | 0.89 | LMNA (0.36) | CRHR1CDK5CDK5R1KDM4EALDH1A1 | |
| SCHEMBL7006275 | 0.88 | LMNA (0.35) | CRHR1CDK5CDK5R1BAZ2BBAZ2A | |
| SCHEMBL6092887 | 0.76 | PTPN1 (0.37) | CRHR1KDM4EALDH1A1LMNAGLA | |
| SCHEMBL6093564 | 0.76 | CDK5 (0.32) | CDK5CDK5R1LMNA | |
| SCHEMBL7010054 | 0.75 | CDK5 (0.33) | CRHR1CDK5CDK5R1LMNA | |
| SCHEMBL7004385 | 0.75 | MAPT (0.37) | CRHR1KDM4EALDH1A1LMNAGLA | |
| SCHEMBL7007266 | 0.72 | MAPT (0.36) | CRHR1KDM4EALDH1A1GAA | |
| SCHEMBL6092967 | 0.72 | PTPN1 (0.35) | KDM4EALDH1A1LMNAGLAGAA | |
| SCHEMBL7006813 | 0.70 | CRHR1 (0.53) | CRHR1 | |
| SCHEMBL6093439 | 0.69 | NPY1R (0.40) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7074929-B2 | Certain alkylene diamine-substituted heterocycles | NEUROGEN CORP. (US) | 2006-07-11 | — | — | US | disclosed |
| US-20040229870-A1 | Certain alkylene diamine-substituted heterocycles | NEUROGEN CORPORATION | 2004-11-18 | — | — | US | disclosed |
| US-6696445-B2 | NEUROPEPTIDE Y RECEPTOR ANTAGONISTS COMPRISING HETEROCYCLIC NITROGEN COMPOUNDS AND/OR PRODRUGS USED FOR PROPHYLAXIS OF EATING AND CARDIOVASCULAR DISORDERS | NEUROGEN CORPORATION | 2004-02-24 | — | — | US | disclosed |
| US-20030158197-A1 | Certain alkylene diamine-substituted heterocycles | NEUROGEN CORPORATION | 2003-08-21 | — | — | US | disclosed |
| US-6506762-B1 | Mono-, bi-, or tricyclic heterocycles may be modified to obtain potent antagonists at the NPY1 receptor. methods for the treatment of physiological disorders associated with an excess of neuropeptide Y. Novel compounds are for eating | NEUROGEN CORPORATION | 2003-01-14 | — | — | US | disclosed |
| EP-1224187-A2 | CERTAIN ALKYLENE DIAMINE-SUBSTITUTED HETEROCYCLES | NEUROGEN CORPORATION (US) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001023389-A2 | CERTAIN ALKYLENE DIAMINE-SUBSTITUTED HETEROCYCLES | NEUROGEN CORPORATION (US) | 2001-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158197-A1 | Certain alkylene diamine-substituted heterocycles | NPY1R, NPY5R, NPY2R | CRHR1 16/4885CDK5 2784/4885CDK5R1 1615/4885 |
| US-20040229870-A1 | Certain alkylene diamine-substituted heterocycles | NPY1R, NPY5R, NPY2R | CRHR1 14/4885CDK5 2869/4885CDK5R1 1801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.